Cormorant Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Cormorant Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,547,181	Closed	-$5.79M	–	54
2023 Q2	$5.79M	Hold	1,547,181	–	–	0.32%	49
2023 Q1	$5.18M	Hold	1,547,181	–	–	0.34%	46
2022 Q4	$7.44M	Hold	1,547,181	–	–	0.5%	43
2022 Q3	$8.8M	Hold	1,547,181	–	–	0.62%	43
2022 Q2	$11M	Hold	1,547,181	–	–	0.83%	38
2022 Q1	$11.2M	Sell	1,547,181 -132,261	-8%	-$898K	0.86%	34
2021 Q4	$15M	Sell	1,679,442 -3,249,314	-66%	-$50.6M	0.89%	31
2021 Q3	$173M	Sell	4,928,756 -1,482,599	-23%	-$41.1M	7.02%	3
2021 Q2	$138M	Hold	6,411,355	–	–	4.68%	3
2021 Q1	$396M	Hold	6,411,355	–	–	8.82%	3
2020 Q4	$260M	Buy	+6,411,355	New	+$207M	6.18%	2

Other funds holding AVIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cormorant Asset Management's AVIR Position: Q3 2023 in Review

Cormorant Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q3 2023, closing a stake of 1,547,181 shares — an estimated $5.79M sold.

Cormorant Asset Management first reported a position in AVIR in Q4 2020 and held it in 11 quarters. The position peaked at $396M in Q1 2021. 119 funds tracked by Wall St. Rank hold AVIR as of Q3 2023.

Cormorant Asset Management reported no remaining Atea Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Cormorant Asset Management sold 1,547,181 Atea Pharmaceuticals shares in Q3 2023, an estimated $5.79M.
Cormorant Asset Management first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 11 quarters.
Cormorant Asset Management's Atea Pharmaceuticals position peaked at $396M in Q1 2021.
119 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2023.

Based on Cormorant Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.